Patents by Inventor Atsuko Ochida

Atsuko Ochida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic NMDA antagonists
    Patent number: 12630509
    Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: May 19, 2026
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shuhei Ikeda, Makoto Kamata, Yuya Oguro, Jumpei Aida, Taisuke Tawaraishi, Takeshi Wakabayashi, Norio Oyabu, Atsuko Ochida, Kouichi Iwanaga, Satoshi Yamamoto, Masataka Murakami, Minoru Nakamura, Fumie Yamaguchi, Takafumi Yukawa
  • Heterocyclic amide compounds having an RORvt inhibitory action
    Patent number: 11851449
    Abstract: The present invention relates to compound (I) or a salt thereof which has a ROR?t inhibitory action. In the formula (I), each symbol is as defined in the specification.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: December 26, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Satoshi Yamamoto, Junya Shirai, Mitsunori Kono, Yoshihide Tomata, Ayumu Sato, Atsuko Ochida, Yoshiyuki Fukase, Shoji Fukumoto, Tsuneo Oda, Hidekazu Tokuhara, Naoki Ishii, Yusuke Sasaki
  • HETEROCYCLIC NMDA ANTAGONISTS
    Publication number: 20230150934
    Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
    Type: Application
    Filed: December 22, 2022
    Publication date: May 18, 2023
    Inventors: Shuhei IKEDA, Makoto KAMATA, Yuya OGURO, Jumpei AIDA, Taisuke TAWARAISHI, Takeshi WAKABAYASHI, Norio OYABU, Atsuko OCHIDA, Kouichi IWANAGA, Satoshi YAMAMOTO, Masataka MURAKAMI, Minoru NAKAMURA, Fumie YAMAGUCHI, Takafumi YUKAWA
  • HETEROCYCLIC NMDA ANTAGONISTS
    Publication number: 20230134307
    Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
    Type: Application
    Filed: December 22, 2022
    Publication date: May 4, 2023
    Inventors: Shuhei IKEDA, Makoto KAMATA, Yuya OGURO, Jumpei AIDA, Taisuke TAWARAISHI, Takeshi WAKABAYASHI, Norio OYABU, Atsuko OCHIDA, Kouichi IWANAGA, Satoshi YAMAMOTO, Masataka MURAKAMI, Minoru NAKAMURA, Fumie YAMAGUCHI, Takafumi YUKAWA
  • HETEROCYCLIC NMDA ANTAGONISTS
    Publication number: 20230002318
    Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
    Type: Application
    Filed: November 12, 2020
    Publication date: January 5, 2023
    Inventors: Shuhei IKEDA, Makoto KAMATA, Yuya OGURO, Jumpei AIDA, Taisuke TAWARAISHI, Takeshi WAKABAYASHI, Norio OYABU, Atsuko OCHIDA, Kouichi IWANAGA, Satoshi YAMAMOTO, Masataka MURAKAMI, Minoru NAKAMURA, Fumie YAMAGUCHI, Takafumi YUKAWA
  • Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function
    Patent number: 11407748
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: August 9, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shinji Nakamura, Satoshi Mikami, Tomoaki Hasui, Tohru Yamashita, Shinji Morimoto, Hidekazu Tokuhara, Norio Oyabu, Masami Yamada, Atsuko Ochida, Kazuaki Takami, Xin Liu
  • AMIDE COMPOUND
    Publication number: 20210277030
    Abstract: The present invention relates to compound (I) or a salt thereof which has a ROR?t inhibitory action. In the formula (I), each symbol is as defined in the specification.
    Type: Application
    Filed: May 10, 2021
    Publication date: September 9, 2021
    Inventors: Satoshi Yamamoto, Junya Shirai, Mitsunori Kono, Yoshihide Tomata, Ayumu Sato, Atsuko Ochida, Yoshiyuki Fukase, Shoji Fukumoto, Tsuneo Oda, Hidekazu Tokuhara, Naoki Ishii, Yusuke Sasaki
  • Heterocyclic amide compounds having RORyT inhibitory action
    Patent number: 11053262
    Abstract: The present invention relates to compound (I) or a salt thereof which has a ROR?t inhibitory action. In the formula (I), each symbol is as defined in the specification.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: July 6, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Satoshi Yamamoto, Junya Shirai, Mitsunori Kono, Yoshihide Tomata, Ayumu Sato, Atsuko Ochida, Yoshiyuki Fukase, Shoji Fukumoto, Tsuneo Oda, Hidekazu Tokuhara, Naoki Ishii, Yusuke Sasaki
  • HETEROCYCLIC COMPOUND
    Publication number: 20200270243
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: October 4, 2018
    Publication date: August 27, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shinji NAKAMURA, Satoshi MIKAMI, Tomoaki HASUI, Tohru YAMASHITA, Shinji MORIMOTO, Hidekazu TOKUHARA, Norio OYABU, Masami YAMADA, Atsuko OCHIDA, Kazuaki TAKAMI, Xin LIU
  • AMIDE COMPOUND
    Publication number: 20200010487
    Abstract: The present invention relates to compound (I) or a salt thereof which has a ROR?t inhibitory action. In the formula (I), each symbol is as defined in the specification.
    Type: Application
    Filed: September 19, 2019
    Publication date: January 9, 2020
    Inventors: Satoshi Yamamoto, Junya Shirai, Mitsunori Kono, Yoshihide Tomata, Ayumu Sato, Atsuko Ochida, Yoshiyuki Fukase, Shoji Fukumoto, Tsuneo Oda, Hidekazu Tokuhara, Naoki Ishii, Yusuke Sasaki
  • Amide compound
    Patent number: 10472376
    Abstract: The present invention relates to compound (I) or a salt thereof which has a ROR?t inhibitory action. In the formula (I), each symbol is as defined in the specification.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: November 12, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Satoshi Yamamoto, Junya Shirai, Mitsunori Kono, Yoshihide Tomata, Ayumu Sato, Atsuko Ochida, Yoshiyuki Fukase, Shoji Fukumoto, Tsuneo Oda, Hidekazu Tokuhara, Naoki Ishii, Yusuke Sasaki
  • HETEROCYCLIC COMPOUND
    Publication number: 20180319812
    Abstract: The present invention relates to compound (I) or a salt thereof which has a ROR?t inhibitory action. wherein each symbol is as defined in the specification.
    Type: Application
    Filed: July 13, 2018
    Publication date: November 8, 2018
    Inventors: Satoshi Yamamoto, Junya Shirai, Hiroyuki Watanabe, Shoji Fukumoto, Tsuneo Oda, Hidekazu Tokuhara, Yoshihide Tomata, Naoki Ishii, Michiko Tawada, Mitsunori Kono, Atsuko Ochida, Takashi Imada, Yoshiyuki Fukase, Tomoya Yukawa
  • Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors
    Patent number: 10093629
    Abstract: Provided are heterocyclic compounds having a ROR?t inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: October 9, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Satoshi Yamamoto, Junya Shirai, Tsuneo Oda, Mitsunori Kono, Atsuko Ochida, Takashi Imada, Hidekazu Tokuhara, Yoshihide Tomata, Naoki Ishii, Michiko Tawada, Yoshiyuki Fukase, Tomoya Yukawa, Shoji Fukumoto
  • Heterocyclic compound
    Patent number: 10053468
    Abstract: The present invention relates to compound (I) or a salt thereof which has a ROR?t inhibitory action. wherein each symbol is as defined in the specification.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: August 21, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Satoshi Yamamoto, Junya Shirai, Hiroyuki Watanabe, Shoji Fukumoto, Tsuneo Oda, Hidekazu Tokuhara, Yoshihide Tomata, Naoki Ishii, Michiko Tawada, Mitsunori Kono, Atsuko Ochida, Takashi Imada, Yoshiyuki Fukase, Tomoya Yukawa
  • Heterocyclic compound
    Patent number: 10000488
    Abstract: The problem of the present invention is to provide a compound having a superior ROR?t inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an ROR?t inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: June 19, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Satoshi Yamamoto, Junya Shirai, Tsuneo Oda, Takashi Imada, Mitsunori Kono, Ayumu Sato, Yoshihide Tomata, Atsuko Ochida, Naoki Ishii, Yusuke Sasaki, Yoshiyuki Fukase, Tomoya Yukawa, Shoji Fukumoto
  • Heterocyclic compound
    Patent number: 9834520
    Abstract: The present invention provides a heterocyclic compound having an ROR?t inhibitory action. The present invention relates to a compound represented by the formula (I): wherein Ar is a the partial structure (1) to the partial structure (5), Q is a bivalent group selected from the group consisting of (Ia)-(If), and B is a ring optionally having substituent(s), or a salt thereof.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: December 5, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Satoshi Yamamoto, Junya Shirai, Yoshiyuki Fukase, Ayumu Sato, Mitsunori Kouno, Yoshihide Tomata, Atsuko Ochida, Kazuko Yonemori, Tsuneo Oda, Tomoya Yukawa
  • HETEROCYCLIC COMPOUND
    Publication number: 20170253591
    Abstract: The problem of the present invention is to provide a compound having a superior ROR?t inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an ROR?t inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.
    Type: Application
    Filed: September 10, 2015
    Publication date: September 7, 2017
    Inventors: Satoshi YAMAMOTO, Junya SHIRAI, Tsuneo ODA, Takashi IMADA, Mitsunori KONO, Ayumu SATO, Yoshihide TOMATA, Atsuko OCHIDA, Naoki ISHII, Yusuke SASAKI, Yoshiyuki FUKASE, Tomoya YUKAWA, Shoji FUKUMOTO
  • HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS
    Publication number: 20170144973
    Abstract: Provided are heterocyclic compounds having a ROR?t inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: June 30, 2015
    Publication date: May 25, 2017
    Applicant: Takenda Pharmaceutical Company Limited
    Inventors: Satoshi YAMAMOTO, Junya SHIRAI, Tsuneo ODA, Mitsunori KONO, Atsuko OCHIDA, Takashi IMADA, Hidekazu TOKUHARA, Yoshihide TOMATA, Naoki ISHII, Michiko TAWADA, Yoshiyuki FUKASE, Tomoya YUKAWA, Shoji FUKUMOTO
  • Heterocyclic compound
    Patent number: 9650343
    Abstract: The present invention provides a heterocyclic compound having a ROR?t inhibitory action. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification. or a salt thereof.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: May 16, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Satoshi Yamamoto, Junya Shirai, Tsuneo Oda, Mitsunori Kono, Atsuko Ochida, Takashi Imada, Hidekazu Tokuhara, Yoshihide Tomata, Naoki Ishii, Michiko Tawada, Yoshiyuki Fukase, Tomoya Yukawa, Shoji Fukumoto
  • Heterocyclic compound
    Patent number: 9630924
    Abstract: The present invention provides a heterocyclic compound having a ROR?t inhibitory action. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification. or a salt thereof.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: April 25, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Satoshi Yamamoto, Junya Shirai, Tsuneo Oda, Mitsunori Kono, Atsuko Ochida, Takashi Imada, Hidekazu Tokuhara, Yoshihide Tomata, Naoki Ishii, Michiko Tawada, Yoshiyuki Fukase, Tomoya Yukawa, Shoji Fukumoto